Roche to Present New Pivotal Data at ASH 2021 from Broad and Comprehensive Portfolio, Challenging Treatment Standards for People with Blood Disorders
Phase III POLARIX trial showed Polivy plus R-CHP was the first treatment in two decades to significantly improve outcomes in newly diagnosed diffuse large B-cell lymphoma (DLBCL) versus the standard of care1… Read More



